Vertex signs agreement to acquire Crinetics for $10bn
The acquisition is expected to close in the third quarter of 2026.
Drug Development
EC approves AbbVie’s Tepkinly combination for follicular lymphoma
Novartis to acquire Myricx Bio in up to $1.5bn deal
Besins Healthcare boosts drug delivery portfolio with UniD deal
SK bioscience to lead Gates Foundation-funded ROTOR project
European Commission approves Novartis’ Itvisma to treat SMA
Insilico Medicine, Takeda partner on AI-driven drug discovery
Inocras, AimedBio team up for cancer treatments
